CLINDASEPTIN 150 MG CAPSULES FOR DOGS

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

CLINDAMYCIN (AS CLINDAMYCIN HYDROCHLORIDE)

Available from:

Chanelle Animal Health Ltd.

ATC code:

QJ01FF01

INN (International Name):

CLINDAMYCIN (AS CLINDAMYCIN HYDROCHLORIDE)

Dosage:

150 Milligram

Pharmaceutical form:

Capsule

Prescription type:

POM

Therapeutic group:

Canine

Therapeutic area:

Clindamycin

Therapeutic indications:

Antibacterial

Authorization status:

Authorised

Authorization date:

2013-06-28

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Clindaseptin 150 mg capsules for dogs.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each capsule contains:
ACTIVE SUBSTANCE:
Clindamycin (as Clindamycin Hydrochloride)
150 mg.
EXCIPIENTS:
For a full list of excipients see section 6.1.
3 PHARMACEUTICAL FORM
Capsule.
The capsule has a lavender body and a maroon cap marked CL150.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of:-
Infected wounds, abscesses and oral cavity/dental infections caused by or associated with clindamycin-sensitive species
of;
_Staphylococcus._
_Streptococcus._
_Bacteroides_
_Fusobacterium necrophorum_
_Clostridium perfringens_
Osteomyelitis
_Staphylococcus aureus_
4.3 CONTRAINDICATIONS
Do not use in cases of known hypersensitivity to clindamycin or lincomycin.
Do not administer to rabbits, hamsters, guinea pigs, chinchillas, horses or ruminants because ingestion of clindamycin
by these species may result in severe gastro-intestinal disturbance.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None known.
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 08/11/2016_
_CRN 7024937_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
During prolonged therapy of one month or greater, periodic liver and kidney function tests and blood counts should be
performed. Patients with severe renal and/or hepatic disturbances accompanied by severe metabolic aberrations should
be dosed with caution and should be monitored by serum examination during clindamycin therapy.
Whenever possible, the veterinary medicinal product should only be used based on susceptibility testing.
SPEC